Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlations.
We treated 21 patients with advanced breast cancer with buserelin, aminoglutethimide and cortisone acetate in an attempt to obtain a complete estrogen blockade both in premenopausal and postmenopausal patients. Ten patients (47%) obtained an objective response without any relevant side-effects. Dealing with hormonal data, it must be outlined that serum testosterone levels decreased significantly in postmenopausal patients, suggesting a possible explanation for the activity of luteinizing hormone-releasing hormone analogue in this group of patients.
Ferrari
V
V
III Div. Medicina Generale, Servizio di Oncologia, Fondazione Beretta, Brescia, Italy.
Zaniboni
A
A
Simoncini
E
E
Marpicati
E
E
Montini
E
E
Moretti
R
R
Marini
G
G
D000328:Adult; D000616:Aminoglutethimide / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D002064:Buserelin / Q000008:administration & dosage*; D003348:Cortisone / Q000008:administration & dosage / Q000031:analogs & derivatives; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D011960:Receptors, Estrogen / Q000032:analysis; D013739:Testosterone / Q000097:blood
D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D000616:Aminoglutethimide; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin; D003348:Cortisone